2024 Q2 Form 10-Q Financial Statement
#000181833124000023 Filed on April 29, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| Revenue | $70.51M | $62.42M |
| YoY Change | 44.77% | 44.7% |
| Cost Of Revenue | $27.56M | $25.01M |
| YoY Change | -7.97% | -10.36% |
| Gross Profit | $42.95M | $37.41M |
| YoY Change | 128.99% | 145.54% |
| Gross Profit Margin | 60.91% | 59.93% |
| Selling, General & Admin | $41.76M | $38.53M |
| YoY Change | -20.5% | -32.57% |
| % of Gross Profit | 97.21% | 102.99% |
| Research & Development | $10.90M | $11.57M |
| YoY Change | -36.39% | -20.73% |
| % of Gross Profit | 25.38% | 30.92% |
| Depreciation & Amortization | $1.712M | $1.742M |
| YoY Change | -74.92% | -66.04% |
| % of Gross Profit | 3.99% | 4.66% |
| Operating Expenses | $52.66M | $50.10M |
| YoY Change | -24.41% | -30.16% |
| Operating Profit | -$10.58M | -$13.66M |
| YoY Change | -79.51% | -77.37% |
| Interest Expense | -$894.0K | -$6.698M |
| YoY Change | -242.81% | -973.27% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$18.78M | -$6.661M |
| YoY Change | -499.07% | 762.82% |
| Pretax Income | -$29.36M | -$20.32M |
| YoY Change | -37.41% | -66.76% |
| Income Tax | -$190.0K | -$100.0K |
| % Of Pretax Income | ||
| Net Earnings | -$29.17M | -$20.24M |
| YoY Change | -37.56% | -66.82% |
| Net Earnings / Revenue | -41.37% | -32.42% |
| Basic Earnings Per Share | -$1.10 | -$0.78 |
| Diluted Earnings Per Share | -$1.10 | -$0.78 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 26.14M shares | 26.05M shares |
| Diluted Shares Outstanding | 26.62M shares | 26.06M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $106.9M | $112.9M |
| YoY Change | -31.81% | -44.08% |
| Cash & Equivalents | $56.08M | $83.67M |
| Short-Term Investments | $50.78M | $29.24M |
| Other Short-Term Assets | $11.35M | $9.974M |
| YoY Change | 1.35% | -59.29% |
| Inventory | $10.32M | $11.62M |
| Prepaid Expenses | $7.441M | |
| Receivables | $25.50M | $28.15M |
| Other Receivables | $693.0K | $772.0K |
| Total Short-Term Assets | $162.2M | $163.4M |
| YoY Change | -23.96% | -39.99% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $56.96M | $57.61M |
| YoY Change | 31.46% | 16.35% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | $165.6M | $169.1M |
| YoY Change | -7.81% | -7.66% |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $4.357M | $4.380M |
| YoY Change | -21.62% | -28.9% |
| Total Long-Term Assets | $226.9M | $231.1M |
| YoY Change | -13.75% | -15.33% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $162.2M | $163.4M |
| Total Long-Term Assets | $226.9M | $231.1M |
| Total Assets | $389.1M | $394.5M |
| YoY Change | -18.32% | -27.65% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $8.134M | $9.477M |
| YoY Change | -67.48% | -74.33% |
| Accrued Expenses | $7.293M | $11.29M |
| YoY Change | -56.45% | -59.04% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $1.100M | $798.0K |
| YoY Change | ||
| Total Short-Term Liabilities | $68.27M | $50.73M |
| YoY Change | -19.08% | -57.38% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $52.16M | $52.29M |
| YoY Change | 734.56% | 736.69% |
| Other Long-Term Liabilities | $12.66M | $20.84M |
| YoY Change | -43.51% | -5.77% |
| Total Long-Term Liabilities | $64.82M | $73.13M |
| YoY Change | 126.16% | 157.85% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $68.27M | $50.73M |
| Total Long-Term Liabilities | $64.82M | $73.13M |
| Total Liabilities | $195.1M | $187.3M |
| YoY Change | 8.2% | -13.61% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.350B | -$1.320B |
| YoY Change | 9.53% | 11.39% |
| Common Stock | $2.000K | $2.000K |
| YoY Change | 0.0% | 0.0% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $194.0M | $207.2M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $389.1M | $394.5M |
| YoY Change | -18.32% | -27.65% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$29.17M | -$20.24M |
| YoY Change | -37.56% | -66.82% |
| Depreciation, Depletion And Amortization | $1.712M | $1.742M |
| YoY Change | -74.92% | -66.04% |
| Cash From Operating Activities | -$4.505M | -$16.41M |
| YoY Change | -91.58% | -70.46% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $1.352M | $443.0K |
| YoY Change | -51.01% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$21.35M | $1.286M |
| YoY Change | 150.87% | |
| Cash From Investing Activities | -$22.70M | $843.0K |
| YoY Change | 101.43% | -282.47% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -391.0K | -$438.0K |
| YoY Change | -105.29% | -100.33% |
| NET CHANGE | ||
| Cash From Operating Activities | -4.505M | -$16.41M |
| Cash From Investing Activities | -22.70M | $843.0K |
| Cash From Financing Activities | -391.0K | -$438.0K |
| Net Change In Cash | -27.60M | -$16.01M |
| YoY Change | -51.9% | -120.89% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$4.505M | -$16.41M |
| Capital Expenditures | $1.352M | $443.0K |
| Free Cash Flow | -$5.857M | -$16.86M |
| YoY Change | -89.59% | -69.66% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-20239000 | usd |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
62422000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
43139000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
25011000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
27903000 | usd |
| CY2024Q1 | us-gaap |
Gross Profit
GrossProfit
|
37411000 | usd |
| CY2023Q1 | us-gaap |
Gross Profit
GrossProfit
|
15236000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11567000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14592000 | usd |
| CY2024Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
16085000 | usd |
| CY2023Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
13452000 | usd |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
22445000 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
43689000 | usd |
| CY2024Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | usd |
| CY2023Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
2120000 | usd |
| CY2024Q1 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
-974000 | usd |
| CY2023Q1 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
-1747000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13660000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-60364000 | usd |
| CY2024Q1 | wgs |
Change In Fair Value Of Warrants And Earn Out Contingent Liabilities
ChangeInFairValueOfWarrantsAndEarnOutContingentLiabilities
|
-6101000 | usd |
| CY2023Q1 | wgs |
Change In Fair Value Of Warrants And Earn Out Contingent Liabilities
ChangeInFairValueOfWarrantsAndEarnOutContingentLiabilities
|
-3453000 | usd |
| CY2024Q1 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-597000 | usd |
| CY2023Q1 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
-35000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
37000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2716000 | usd |
| CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-6661000 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-772000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-20321000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-61136000 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-82000 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-147000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-20239000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-60989000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-134000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
0 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-20373000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-60989000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
228017000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-20239000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
24000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
-451000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-134000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
207217000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
253705000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-60989000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
266000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
48000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
328469000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-60989000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
5248000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
8636000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
-451000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
48000 | usd |
| CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
6101000 | usd |
| CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
3453000 | usd |
| CY2024Q1 | us-gaap |
Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
|
-82000 | usd |
| CY2023Q1 | us-gaap |
Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
|
-147000 | usd |
| CY2024Q1 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
40000 | usd |
| CY2023Q1 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
0 | usd |
| CY2024Q1 | wgs |
Change In Third Party Payor Reserves
ChangeInThirdPartyPayorReserves
|
193000 | usd |
| CY2023Q1 | wgs |
Change In Third Party Payor Reserves
ChangeInThirdPartyPayorReserves
|
1070000 | usd |
| CY2024Q1 | wgs |
Gain Loss On Debt Forgiveness
GainLossOnDebtForgiveness
|
0 | usd |
| CY2023Q1 | wgs |
Gain Loss On Debt Forgiveness
GainLossOnDebtForgiveness
|
2750000 | usd |
| CY2024Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | usd |
| CY2023Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
2120000 | usd |
| CY2024Q1 | us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
846000 | usd |
| CY2023Q1 | us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
274000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-4220000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-9723000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2877000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-1331000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-4733000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-13400000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
4293000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
2789000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-16413000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-55560000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
443000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
5167000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
0 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
598000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
0 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
5855000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
0 | usd |
| CY2024Q1 | us-gaap |
Payments To Develop Software
PaymentsToDevelopSoftware
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments To Develop Software
PaymentsToDevelopSoftware
|
462000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
843000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-462000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
135439000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
24000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
266000 | usd |
| CY2024Q1 | us-gaap |
Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
|
0 | usd |
| CY2023Q1 | us-gaap |
Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
|
2000000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
462000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
1047000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-438000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
132658000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-16008000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
76636000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
100668000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
138303000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
84660000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
214939000 | usd |
| CY2024Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
2019000 | usd |
| CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
583000 | usd |
| CY2024Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
300000 | usd |
| CY2023Q1 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
104000 | usd |
| CY2024Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
36000 | usd |
| CY2023Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
1073000 | usd |
| CY2024Q1 | wgs |
Software Development Costs Incurred But Not Yet Paid
SoftwareDevelopmentCostsIncurredButNotYetPaid
|
0 | usd |
| CY2023Q1 | wgs |
Software Development Costs Incurred But Not Yet Paid
SoftwareDevelopmentCostsIncurredButNotYetPaid
|
157000 | usd |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Organization and Description of Business <div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GeneDx Holdings Corp., through its subsidiary GeneDx, LLC, provides genomics-related diagnostic and information services and pursues genomics medical research. GeneDx utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyzes information about patient-specific genetic variation and generates test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings’ operating subsidiaries primarily serve healthcare professionals who work with their patients and bills third-party payors across the United States.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the Company raised approximately $150.0 million in gross proceeds and announced the closing of an underwritten public offering of 9,962,316 shares of its Class A common stock and a concurrent registered direct offering of 2,353,436 shares of its Class A common stock. The net offering proceeds received after deducting underwriters' discounts and commissions payable by the Company were approximately $135.4 million. On April 17, 2023, following the Company’s receipt of stockholder approval for the issuance, the Company issued the remaining 676,868 shares of the Company’s Class A common stock in its previously announced registered direct offering for gross proceeds of approximately $7.6 million.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herein or unless the context otherwise requires, references in these notes to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“GeneDx Holdings” refers to GeneDx Holdings Corp., a Delaware corporation (f/k/a Sema4 Holdings Corp. (“Sema4 Holdings”));</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">“Legacy GeneDx” refers to GeneDx, LLC, a Delaware limited liability company (formerly, GeneDx, Inc., a New Jersey corporation), which we acquired on April 29, 2022 (the “Acquisition”);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“Legacy Sema4” refers to Mount Sinai Genomics, Inc. d/b/a as Sema4, a Delaware corporation, which consummated the business combination with CM Life Sciences, Inc. (“CMLS”) on July 22, 2021 (the “Business Combination”); and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“we,” “us” and “our,” the “Company” and “GeneDx” refer, as the context requires, to:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Legacy Sema4 prior to the Business Combination, and GeneDx Holdings and its consolidated subsidiaries following the consummation of the Business Combination; and</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Legacy GeneDx prior to the Acquisition, and GeneDx Holdings and its consolidated subsidiaries following the consummation of the Acquisition.</span></div> | |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, potential or actual claims for recoupment from third-party payors, the valuation of stock-based awards, the valuation of warrant liabilities, income taxes and intangible assets. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates, judgments and assumptions.</span></div> | |
| CY2024Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating concentration of credit risk. Significant patients and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of March 31, 2024 and December 31, 2023 were primarily from large managed care insurance companies, institutional billed accounts, and data arrangements. There was one individual client that accounted for approximately 14% of accounts receivable as of March 31, 2024. The Company does not require collateral as a means to mitigate customer credit risk.</span></div> | |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
62422000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
43139000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
|
5700000 | usd |
| CY2023Q1 | us-gaap |
Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
|
2700000 | usd |
| CY2024Q1 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
2600000 | usd |
| CY2024Q1 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P12M | |
| CY2023Q4 | us-gaap |
Capitalized Contract Cost Net
CapitalizedContractCostNet
|
0 | usd |
| CY2024Q1 | us-gaap |
Capitalized Contract Cost Net
CapitalizedContractCostNet
|
0 | usd |
| CY2024Q1 | us-gaap |
Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
|
400000 | usd |
| CY2023Q1 | us-gaap |
Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
|
600000 | usd |
| CY2021Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
666516 | shares |
| CY2024Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
666515 | shares |
| CY2024Q1 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P5Y | |
| CY2024Q1 | wgs |
Class Of Warrant Or Right Target Share Price Of Warrants Or Rights For Redemption
ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption
|
594.00 | |
| CY2024Q1 | wgs |
Redemption Price Per Warrant
RedemptionPricePerWarrant
|
0.33 | |
| CY2024Q1 | wgs |
Number Of Days For Written Notice Of Redemption
NumberOfDaysForWrittenNoticeOfRedemption
|
30 | day |
| CY2024Q1 | wgs |
Common Stock Threshold Trading Days
CommonStockThresholdTradingDays
|
30 | day |
| CY2024Q1 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
|
79031000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
|
78931000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
|
47730000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
|
46452000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
|
31301000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
|
32479000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1700000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
5100000 | usd |
| CY2023Q1 | us-gaap |
Impairment Of Leasehold
ImpairmentOfLeasehold
|
1600000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1742000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
5130000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
196000000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
26881000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
169119000 | usd |
| CY2017Q2 | wgs |
Related Party Transaction Funding Commitment To Be Received Maximum
RelatedPartyTransactionFundingCommitmentToBeReceivedMaximum
|
55000000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
|
497000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
1211000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
1235000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
1260000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
51285000 | usd |
| CY2024Q1 | wgs |
Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
|
762000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
56250000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
798000 | usd |
| CY2024Q1 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
3159000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
52293000 | usd |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
-451000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
48000 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-100000 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-100000 | usd |
| CY2024Q1 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.0042 | |
| CY2023Q1 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.0030 | |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-20239000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-60989000 | usd |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
26062170 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
26062170 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
20061945 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
20061945 | shares |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.78 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.78 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.04 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.04 | |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4052558 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3216517 | shares |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
11292000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12154000 | usd |
| CY2024Q1 | us-gaap |
Accrued Insurance Current
AccruedInsuranceCurrent
|
11641000 | usd |
| CY2023Q4 | us-gaap |
Accrued Insurance Current
AccruedInsuranceCurrent
|
15064000 | usd |
| CY2024Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
32410000 | usd |
| CY2024Q1 | us-gaap |
Restructuring Costs
RestructuringCosts
|
800000 | usd |
| CY2023Q1 | us-gaap |
Restructuring Costs
RestructuringCosts
|
700000 | usd |
| CY2023Q3 | us-gaap |
Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
|
50 | position |
| CY2023Q4 | us-gaap |
Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
|
35 | position |
| CY2023Q4 | us-gaap |
Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
|
0.10 | |
| CY2023Q4 | us-gaap |
Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
|
-40000000 | usd |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
83673000 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
99681000 | usd |
| CY2024Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
987000 | usd |
| CY2023Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
987000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
84660000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
100668000 | usd |
| CY2024Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
9477000 | usd |
| CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
10238000 | usd |
| CY2023Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
37456000 | usd |
| CY2024Q1 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
9995000 | usd |
| CY2023Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
12465000 | usd |
| CY2024Q1 | wgs |
Accrued Severance Current
AccruedSeveranceCurrent
|
1354000 | usd |
| CY2023Q4 | wgs |
Accrued Severance Current
AccruedSeveranceCurrent
|
1853000 | usd |
| CY2024Q1 | us-gaap |
Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
|
1891000 | usd |
| CY2023Q4 | us-gaap |
Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
|
2018000 | usd |
| CY2024Q1 | wgs |
Warrant Liability
WarrantLiability
|
8836000 | usd |
| CY2023Q4 | wgs |
Warrant Liability
WarrantLiability
|
2735000 | usd |
| CY2024Q1 | wgs |
Third Party Payor Reserve Non Current
ThirdPartyPayorReserveNonCurrent
|
12000000 | usd |
| CY2023Q4 | wgs |
Third Party Payor Reserve Non Current
ThirdPartyPayorReserveNonCurrent
|
12000000 | usd |
| CY2024Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
20836000 | usd |
| CY2023Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
14735000 | usd |
| CY2024Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
2 | segment |
| CY2024Q1 | us-gaap |
Gross Profit
GrossProfit
|
37411000 | usd |
| CY2023Q1 | us-gaap |
Gross Profit
GrossProfit
|
15236000 | usd |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false |
